MADDEN SECURITIES Corp lowered its position in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 13.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,522 shares of the biopharmaceutical company’s stock after selling 847 shares during the quarter. MADDEN SECURITIES Corp’s holdings in Pfizer were worth $283,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also added to or reduced their stakes in PFE. Assenagon Asset Management S.A. increased its holdings in shares of Pfizer by 528.9% during the third quarter. Assenagon Asset Management S.A. now owns 12,401,164 shares of the biopharmaceutical company’s stock valued at $542,675,000 after acquiring an additional 10,429,412 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Pfizer by 13.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 59,828,849 shares of the biopharmaceutical company’s stock valued at $3,097,341,000 after acquiring an additional 6,972,650 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of Pfizer during the first quarter valued at $311,238,000. Vanguard Group Inc. increased its holdings in shares of Pfizer by 1.1% during the third quarter. Vanguard Group Inc. now owns 493,584,761 shares of the biopharmaceutical company’s stock valued at $21,599,270,000 after acquiring an additional 5,139,634 shares in the last quarter. Finally, First Trust Advisors LP increased its holdings in shares of Pfizer by 108.3% during the first quarter. First Trust Advisors LP now owns 7,909,665 shares of the biopharmaceutical company’s stock valued at $409,483,000 after acquiring an additional 4,112,528 shares in the last quarter. Hedge funds and other institutional investors own 67.62% of the company’s stock.
Pfizer Stock Performance
Pfizer stock opened at $40.10 on Friday. Pfizer Inc. has a 1-year low of $39.23 and a 1-year high of $56.32. The company’s 50-day moving average is $43.26 and its 200 day moving average is $46.03. The firm has a market capitalization of $225.33 billion, a P/E ratio of 7.32, a price-to-earnings-growth ratio of 1.35 and a beta of 0.64. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.22 and a quick ratio of 1.00.
Analyst Ratings Changes
PFE has been the subject of several research analyst reports. Atlantic Securities reduced their price objective on Pfizer from $50.00 to $46.00 and set a “neutral” rating for the company in a report on Wednesday, February 1st. Berenberg Bank set a $40.00 price objective on Pfizer in a report on Tuesday, February 7th. UBS Group set a $45.00 price objective on Pfizer in a report on Tuesday, March 14th. BMO Capital Markets reduced their price objective on Pfizer from $55.00 to $53.00 and set an “outperform” rating for the company in a report on Wednesday, February 1st. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $75.00 price objective on shares of Pfizer in a report on Wednesday, February 1st. Nine investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $50.38.
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.